SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-042138
Filing Date
2023-11-20
Accepted
2023-11-20 16:51:55
Documents
56
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2181390
2 ex31-1.htm EX-31.1 19804
3 ex31-2.htm EX-31.2 20294
4 ex32-1.htm EX-32.2 8998
5 ex32-2.htm EX-32.2 9574
  Complete submission text file 0001493152-23-042138.txt   11288416

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE atrx-20230930.xsd EX-101.SCH 51620
7 XBRL CALCULATION FILE atrx-20230930_cal.xml EX-101.CAL 38652
8 XBRL DEFINITION FILE atrx-20230930_def.xml EX-101.DEF 244355
9 XBRL LABEL FILE atrx-20230930_lab.xml EX-101.LAB 404342
10 XBRL PRESENTATION FILE atrx-20230930_pre.xml EX-101.PRE 312674
50 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1835836
Mailing Address P.O. BOX 2161 WAKE FOREST NC 27588
Business Address P.O. BOX 2161 WAKE FOREST NC 27588 919-578-5901
Adhera Therapeutics, Inc. (Filer) CIK: 0000737207 (see all company filings)

IRS No.: 112658569 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-13789 | Film No.: 231423392
SIC: 2834 Pharmaceutical Preparations